MAPT and Alzheimer disease: The importance of structural MRI in the assessment of AD was underlined by its inclusion in the new diagnostic criteria (Dubois et al., 2007) along with temporoparietal hypometabolism as seen in positron emission tomography (PET) (Mosconi et al., 2008), positivity on amyloid imaging as seen in PET (Johnson et al., 2013), and abnormal neuronal cerebrospinal fluid (CSF) biomarkers (tau and/or Aβ) (Brier et al., 2016; Bjerke and Engelborghs, 2018; Blennow and Zetterberg, 2018).